1
|
Di Marco CN, Terrell L, Sanchez R, Rueda L, Shuster L, Nartey EN, McHugh C, Mack JF, Shu A, Tian X, Medina JR, Rivero R, Manetsch R, Heerding D, Mangatt B. Design and synthesis of aminopyridine containing biaryls reducing c-MYC protein levels in cells. Bioorg Med Chem Lett 2023; 92:129385. [PMID: 37339719 DOI: 10.1016/j.bmcl.2023.129385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Accepted: 06/16/2023] [Indexed: 06/22/2023]
Abstract
The c-MYC oncogene transcription factor has been implicated in cell cycle regulation controlling cell growth and proliferation. It is tightly regulated in normal cells, but has been shown to be deregulated in cancer cells, and is thus an attractive target for oncogenic therapies. Building upon previous SAR, a series of analogues containing benzimidazole core replacements were prepared and evaluated, leading to the identification of imidazopyridazine compounds that were shown to possess equivalent or improved c-MYC HTRF pEC50 values, lipophilicity, solubility, and rat pharmacokinetics. The imidazopyridazine core was therefore determined to be superior to the original benzimidazole core and a viable alternate for continued lead optimization and medicinal chemistry campaigns.
Collapse
Affiliation(s)
- Christina N Di Marco
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA; Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA.
| | - Lamont Terrell
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Robert Sanchez
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Lourdes Rueda
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Leanna Shuster
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | | | - Charles McHugh
- Drug Metabolism and Pharmacokinetics, Research In Vivo/In Vitro Translation, GSK, Collegeville, PA 19426, USA
| | - James F Mack
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Arthur Shu
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Xinrong Tian
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Jesus R Medina
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Ralph Rivero
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Roman Manetsch
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA; Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA; Center for Drug Discovery, Northeastern University, Boston, MA 02115, USA; Barnett Institute of Chemical and Biological Analysis, Northeastern University, Boston, MA 02115, USA
| | - Dirk Heerding
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Biju Mangatt
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| |
Collapse
|
2
|
Tian X, Suarez D, Thomson D, Li W, King EA, LaFrance L, Boehm J, Barton L, Di Marco C, Martyr C, Thalji R, Medina J, Knight S, Heerding D, Gao E, Nartey E, Cecconie T, Nixon C, Zhang G, Berrodin TJ, Phelps C, Patel A, Bai X, Lind K, Prabhu N, Messer J, Zhu Z, Shewchuk L, Reid R, Graves AP, McHugh C, Mangatt B. Discovery of Proline-Based p300/CBP Inhibitors Using DNA-Encoded Library Technology in Combination with High-Throughput Screening. J Med Chem 2022; 65:14391-14408. [DOI: 10.1021/acs.jmedchem.2c00670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
- Xinrong Tian
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Dominic Suarez
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Douglas Thomson
- Cellzome GmbH, A GlaxoSmithKline Company, Meyerhofstrasse 1, 69117 Heidelberg, Germany
| | - William Li
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Elizabeth A. King
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Louis LaFrance
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Jeffrey Boehm
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Linda Barton
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Christina Di Marco
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Cuthbert Martyr
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Reema Thalji
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Jesus Medina
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Steven Knight
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Dirk Heerding
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Enoch Gao
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Eldridge Nartey
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Ted Cecconie
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Christopher Nixon
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Guofeng Zhang
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Thomas J. Berrodin
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Christopher Phelps
- New Chemical Entity Molecular Discovery, GlaxoSmithKline, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Amish Patel
- New Chemical Entity Molecular Discovery, GlaxoSmithKline, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Xiaopeng Bai
- New Chemical Entity Molecular Discovery, GlaxoSmithKline, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Ken Lind
- New Chemical Entity Molecular Discovery, GlaxoSmithKline, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Ninad Prabhu
- New Chemical Entity Molecular Discovery, GlaxoSmithKline, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Jeffrey Messer
- New Chemical Entity Molecular Discovery, GlaxoSmithKline, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Zhengrong Zhu
- New Chemical Entity Molecular Discovery, GlaxoSmithKline, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Lisa Shewchuk
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Rob Reid
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Alan P. Graves
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Charles McHugh
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Biju Mangatt
- Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| |
Collapse
|
3
|
Pappalardi MB, Keenan K, Cockerill M, Kellner WA, Stowell A, Sherk C, Wong K, Pathuri S, Briand J, Steidel M, Chapman P, Groy A, Wiseman AK, McHugh CF, Campobasso N, Graves AP, Fairweather E, Werner T, Raoof A, Butlin RJ, Rueda L, Horton JR, Fosbenner DT, Zhang C, Handler JL, Muliaditan M, Mebrahtu M, Jaworski JP, McNulty DE, Burt C, Eberl HC, Taylor AN, Ho T, Merrihew S, Foley SW, Rutkowska A, Li M, Romeril SP, Goldberg K, Zhang X, Kershaw CS, Bantscheff M, Jurewicz AJ, Minthorn E, Grandi P, Patel M, Benowitz AB, Mohammad HP, Gilmartin AG, Prinjha RK, Ogilvie D, Carpenter C, Heerding D, Baylin SB, Jones PA, Cheng X, King BW, Luengo JI, Jordan AM, Waddell I, Kruger RG, McCabe MT. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer 2021; 2:1002-1017. [PMID: 34790902 DOI: 10.1038/s43018-021-00249-x] [Citation(s) in RCA: 88] [Impact Index Per Article: 29.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Accepted: 07/27/2021] [Indexed: 05/22/2023]
Abstract
DNA methylation, a key epigenetic driver of transcriptional silencing, is universally dysregulated in cancer. Reversal of DNA methylation by hypomethylating agents, such as the cytidine analogs decitabine or azacytidine, has demonstrated clinical benefit in hematologic malignancies. These nucleoside analogs are incorporated into replicating DNA where they inhibit DNA cytosine methyltransferases DNMT1, DNMT3A and DNMT3B through irreversible covalent interactions. These agents induce notable toxicity to normal blood cells thus limiting their clinical doses. Herein we report the discovery of GSK3685032, a potent first-in-class DNMT1-selective inhibitor that was shown via crystallographic studies to compete with the active-site loop of DNMT1 for penetration into hemi-methylated DNA between two CpG base pairs. GSK3685032 induces robust loss of DNA methylation, transcriptional activation and cancer cell growth inhibition in vitro. Due to improved in vivo tolerability compared with decitabine, GSK3685032 yields superior tumor regression and survival mouse models of acute myeloid leukemia.
Collapse
Affiliation(s)
- Melissa B Pappalardi
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Kathryn Keenan
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Mark Cockerill
- Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK
- These authors contributed equally: Mark Cockerill, Wendy A. Kellner
| | - Wendy A Kellner
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
- These authors contributed equally: Mark Cockerill, Wendy A. Kellner
| | - Alexandra Stowell
- Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK
| | - Christian Sherk
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Kristen Wong
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Sarath Pathuri
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jacques Briand
- Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA
| | - Michael Steidel
- Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany
| | - Philip Chapman
- Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK
| | - Arthur Groy
- Future Pipeline Discovery, GlaxoSmithKline, Collegeville, PA, USA
| | - Ashley K Wiseman
- Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA
| | - Charles F McHugh
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Nino Campobasso
- Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA
| | - Alan P Graves
- Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA
| | - Emma Fairweather
- Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK
| | - Thilo Werner
- Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany
| | - Ali Raoof
- Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK
| | - Roger J Butlin
- Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK
| | - Lourdes Rueda
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - John R Horton
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - David T Fosbenner
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Cunyu Zhang
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Jessica L Handler
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Morris Muliaditan
- Drug Metabolism and Pharmacokinetics Modelling, GlaxoSmithKline, Stevenage, UK
| | - Makda Mebrahtu
- Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA
| | - Jon-Paul Jaworski
- Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA
| | - Dean E McNulty
- Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA
| | - Charlotte Burt
- Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK
| | - H Christian Eberl
- Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany
| | - Amy N Taylor
- Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA
| | - Thau Ho
- Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA
| | - Susan Merrihew
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Shawn W Foley
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Anna Rutkowska
- Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany
| | - Mei Li
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Stuart P Romeril
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Kristin Goldberg
- Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK
| | - Xing Zhang
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Christopher S Kershaw
- Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK
| | - Marcus Bantscheff
- Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany
| | | | - Elisabeth Minthorn
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Paola Grandi
- Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany
| | - Mehul Patel
- Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA
| | | | - Helai P Mohammad
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | | | - Rab K Prinjha
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Donald Ogilvie
- Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK
| | | | - Dirk Heerding
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Stephen B Baylin
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
| | - Peter A Jones
- Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA
| | - Xiaodong Cheng
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Bryan W King
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Juan I Luengo
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Allan M Jordan
- Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK
| | - Ian Waddell
- Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK
| | - Ryan G Kruger
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| | - Michael T McCabe
- Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA
| |
Collapse
|